Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy

ABSTRACT

Purpose: Fibroblast growth factor 23 (FGF23) is a hormone regulating phosphate metabolism. Excessive actions of FGF23 cause several types of FGF23-related hypophosphatemic rickets/osteomalacia. Recently, it was reported that FGF23 levels were independently correlated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). In addition, FGF23 was also shown to cause cardiac hypertrophy directly acting on cardiomyocytes. However, there is no study indicating the correlation between FGF23 and LVH in adult patients with FGF23-related hypophosphatemic rickets/osteomalacia. Therefore, we examined the existence of LVH in these patients. Materials and methods: We recruited consecutive 24 patients with FGF23-related hypophosphatemic diseases. Their serum intact FGF23 levels and the parameters associated with LVH, including left ventricular mass index (LVMI), relative wall thickness (RWT), Sokolow-Lyon voltage, and Cornell product, were measured. The correlations between FGF23 and these parameters were examined. Results: The participants did not show LVH on the whole. In addition, no significant correlation was observed by these examinations. Conclusion: It seems unlikely that FGF23 levels are the apparent determinant of the cardiac mass in patients with FGF23-related hypophosphatemic rickets/osteomalacia.

KEYWORDS:

• FGF23-related hypophosphatemic rickets/osteomalacia
• fibroblast growth factor 23
• left ventricular hypertrophy

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.